- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01000649
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This was a multi-centre, double-blind, randomized, placebo-controlled, parallel group trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of FE 202158 (using three ascending doses) in patients with vasodilatory hypotension in early septic shock, when given as continuous infusion for up to 7 days.
The trial comprised of three treatment arms where FE 202158 was administered in 1.25 ng, 2.5 ng and 3.75 ng dose, respectively. A placebo arm was also included in the trial where patients received isotonic saline.
Efficacy of FE 202158 was determined by evaluating its ability to maintain mean arterial pressure (MAP) >60 mmHg and its modulating effect on inflammatory markers. Effects of FE 202158 on other variables like vital signs, morbidity, mortality and pulmonary function were also determined.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Brussels, Belgia
- Clinique Universitaire St-Luc
-
Brussels, Belgia
- Erasme Hospital (Free University of Brussels)
-
Brussels, Belgia
- University Hospital Vrije Universiteit
-
Dinant, Belgia
- Service des Soins Intensits
-
-
-
-
-
Vancouver, Canada
- Royal Columbian Hospital
-
Vancouver, Canada
- St. Paul´s Hospital
-
-
-
-
-
Bispebjerg, Danmark
- Bispebjerg Hospital
-
Copenhagen, Danmark
- Rigshospitalet
-
Hillerød, Danmark
- Hillerød Hospital
-
Hvidovre, Danmark
- Hvidovre Hospital
-
-
-
-
Delaware
-
Newark, Delaware, Forente stater
- Christiana Care Health System
-
-
Massachusetts
-
Springfield, Massachusetts, Forente stater
- Baystate Medical Center
-
-
Minnesota
-
Duluth, Minnesota, Forente stater
- Division of Education and Research SMDC Health System
-
-
New Jersey
-
Camden, New Jersey, Forente stater
- Cooper University Hospital
-
-
New York
-
New York, New York, Forente stater
- Mount Sinai School of Medicine
-
-
Texas
-
Houston, Texas, Forente stater
- Baylor College of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Signed informed consent form by the patient or a legal representative according to local regulations
- Man or woman 18 years of age or older
- Proven or suspected infection
- Low blood pressure
- Signs of decreased circulation in the tissues
- Willing to use an adequate barrier method or hormonal method of contraception, if not abstinent, from the day of informed consent to one week after the end of infusion of study medication.
Exclusion Criteria:
- Present or a history (within the last 5 years) of acute coronary syndrome (myocardial infarction or unstable angina). Patients who have been asymptomatic for 6 months after coronary revascularisation are eligible.
- Hypovolaemia suspected on clinical grounds, e.g. cold extremities with delayed capillary filling, low cardiac filling pressure, marked systolic or pulse pressure variation or positive leg raising test.
- Known or suspected cardiac failure
- Pregnancy or breastfeeding
- Any cause of hypotension other than early septic shock
- Use of vasopressin or terlipressin for blood pressure support during the current hospital admission
- Proven or suspected acute mesenteric ischemia, as judged by the investigator
- Known episode of septic shock within 1 month prior to randomisation
- Underlying chronic heart disease
- Traumatic brain injury
- Present hospitalisation with burn injury
- Symptomatic peripheral vascular disease including Raynaud's syndrome
- Previously randomized in this trial
- Intake of an investigational drug within the last 3 months (or longer if judged by the Investigator to possibly influence the outcome of the current study)
- Known participation in another clinical trial
- Considered by the investigator to be unsuitable to participate in the trial for any other reason
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: FE 202158 1.25
Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min. FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use. |
FE 202158 at dose 1.25 ng/kg/min infused.
|
Eksperimentell: FE 202158 2.5
Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min. FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use. |
FE 202158 at dose 2.5 ng/kg/min infused.
|
Eksperimentell: FE 202158 3.75
Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min. FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use. |
FE 202158 at dose 3.75 ng/kg/min infused.
|
Placebo komparator: PLCBO
Patients in the arm received an intravenous infusion for up to 7 days of placebo.
|
Isotonic saline infused.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of Patients Maintaining Target Mean Arterial Pressure (MAP) (>60 mmHg) With no Open Label NE (Norepinephrine)
Tidsramme: Day 1 up to Day 7
|
Data were evaluated for target MAP of ≥ 60 mmHg. A 95% confidence interval (CI) was calculated and presented using Clopper-Pearson method. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Proportion of Patients Maintaining Target MAP (>60) Irrespective of Open Label NE
Tidsramme: Day 1 up to Day 7
|
Data were evaluated for target MAP of ≥ 60 mmHg. A 95% confidence interval (CI) was calculated and presented using Clopper-Pearson method. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Cumulative Dose of Open Label NE.
Tidsramme: Day 1 up to Day 7
|
Cumulative Dose of Open Label NE over 7 days. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Infusion Rates of Open Label NE.
Tidsramme: Day 1 up to Day 7
|
Mean open label NE infusion rate within each predefined time period. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pharmacokinetic (PK) Parameter in Patients : Steady State Concentration
Tidsramme: Day 1 up to Day 7
|
PK parameters were calculated using nonlinear 2-compartment population PK model with random patient effects on clearance and volume of distribution. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
PK Parameter in Patients : Time to Steady State
Tidsramme: Day 1 up to Day 7
|
PK parameters were calculated using nonlinear 2-compartment population PK model with random patient effects on clearance and volume of distribution. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
PK Parameter in Patients : Clearance
Tidsramme: Day 1 up to Day 7
|
PK parameters were calculated using nonlinear 2-compartment population PK model with random patient effects on clearance and volume of distribution. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
PK Parameter in Patients : Steady State Volume of Distribution
Tidsramme: Day 1 up to Day 7
|
PK parameters were calculated using nonlinear 2-compartment population PK model with random patient effects on clearance and volume of distribution. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
PK Parameter in Patients : Initial Elimination Half-life
Tidsramme: Day 1 up to Day 7
|
PK parameters were calculated using nonlinear 2-compartment population PK model with random patient effects on clearance and volume of distribution. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
PK Parameter in Patients : Terminal Elimination Half-life
Tidsramme: Day 1 up to Day 7
|
PK parameters were calculated using nonlinear 2-compartment population PK model with random patient effects on clearance and volume of distribution. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Change From Baseline in C-reactive Protein (CRP)
Tidsramme: Day 1 up to Day 7
|
The change from Baseline in CRP levels were analysed and presented as per the planned time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Change From Baseline in Tumor Necrosis Factor (TNF)-Alpha
Tidsramme: At Day 1, Day 2, Day 4, and Day 7
|
The change from Baseline in TNF-alpha levels were analysed and presented as per the planned time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 1, Day 2, Day 4, and Day 7
|
Change From Baseline in Interleukin-6 (IL-6)
Tidsramme: At Day 1, Day 2, Day 4, and Day 7
|
The change from Baseline in IL-6 levels were analysed and presented as per the planned time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 1, Day 2, Day 4, and Day 7
|
Change From Baseline in Interleukin-10 (IL-10)
Tidsramme: At Day 1, Day 2, Day 4, and Day 7
|
The change from Baseline in IL-10 levels were analysed and presented as per the planned time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 1, Day 2, Day 4, and Day 7
|
Change From Baseline in Interleukin-1 Receptor (IL-1R) Antagonist
Tidsramme: At Day 1, Day 2, Day 4, and Day 7
|
The change from Baseline in IL-1R levels were analysed and presented as per the planned time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 1, Day 2, Day 4, and Day 7
|
Change From Baseline in Heart Rate
Tidsramme: Day 1 up to Day 7
|
The change from Baseline in heart rate was analysed and presented as per the planned time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Change From Baseline in Fluid Balance
Tidsramme: Day 1 up to Day 7
|
The change from Baseline in fluid balance were analysed and presented as per the planned time points. The fluid balance was adjusted for length of time interval and weight. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
SOFA Score
Tidsramme: Day 1 up to Day 7, Day 14 and Day 29
|
The SOFA score, is used to track a patient's status during the stay in an intensive care unit. This scoring system is used to determine the extent of a person's organ function or rate of failure. The scoring system comprise of scores for six different system: Respiratory System; Nervous System; Cardiovascular System; Liver; Coagulation; and Renal System. Score for each system ranges from 0-4 (0=normal, 4=worst). Total SOFA score is a sum of the individual system score and range from 0 to 24, 0 being the better and 24 being the worst patient status. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7, Day 14 and Day 29
|
Pulmonary Function : Change From Baseline in PaO2/FiO2
Tidsramme: Day 1 up to Day 7
|
Change from Baseline in PaO2/FiO2 was observed at each time-point. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Pulmonary Function : Change From Baseline in Tidal Volume
Tidsramme: Day 1 up to Day 7
|
Change from Baseline in tidal volume was observed at each time-point. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Change From Baseline in Arterial Blood Gas (Lactate)
Tidsramme: Day 1 up to Day 7
|
Change from Baseline in arterial blood gas (lactate) was observed at each time-point. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Days Alive and Free of Any Organ Dysfunction at Day 7
Tidsramme: At Day 7
|
Percentage of days alive and free of any organ dysfunction (i.e. no. of days divided by 7). The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 7
|
Percentage of Patients Alive and Free of All Vasopressors
Tidsramme: At Day 7, Day 14 and Day 28
|
Percentage of patients alive and free of all vasopressors was assessed on Days 7, 14, and 28. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 7, Day 14 and Day 28
|
Percentage of Days Alive and Free of Dialysis
Tidsramme: At Day 7, Day 14 and Day 28
|
Percentage of days alive and free of dialysis was assessed on Days 7, 14, and 28. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 7, Day 14 and Day 28
|
Percentage of Days Alive and Free of Ventilation
Tidsramme: At Day 7
|
Percentage of days alive and free of ventilation was assessed on Days 7, 14, and 28. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 7
|
Mortality
Tidsramme: At Day 1, 7, 14, and 28
|
Mortality was assessed as percentage of patients dead at pre-specified time points. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
At Day 1, 7, 14, and 28
|
Incidence of Abnormal Changes in ECG
Tidsramme: Day 1 up to Day 7
|
The number of patients having abnormal changes in ECG variables during the trial period was presented. The patients (n=2) in the FE 202158 3.75 ng/kg/min dose group were both discontinued within 5 hours after start of infusion. Therefore, no adequate data was available to perform the analysis for the outcome. |
Day 1 up to Day 7
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Russell JA, Vincent JL, Kjolbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre PF, Grundemar L. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017 Aug 15;21(1):213. doi: 10.1186/s13054-017-1798-7.
- Rehberg S, Yamamoto Y, Sousse L, Bartha E, Jonkam C, Hasselbach AK, Traber LD, Cox RA, Westphal M, Enkhbaatar P, Traber DL. Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol. 2012 Nov 15;303(10):H1245-54. doi: 10.1152/ajpheart.00390.2012. Epub 2012 Sep 7.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FE 202158 CS02
- EudraCT: 2009-010798-19
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Septisk sjokk
-
Cairo UniversityFullført
-
Cairo UniversityRekruttering
-
Nepal Health Research CouncilFogarty International Center of the National Institute of HealthRekruttering
-
Hospices Civils de LyonRekrutteringToxic Shock Syndrome stafylokokkerFrankrike
-
National Institute of Allergy and Infectious Diseases...Fullført
-
Arrowhead Regional Medical CenterFullførtBrannsår | Mangel på askorbinsyre | Væske og elektrolytt ubalanse | Forbrenningsgrad andre | Forbrenningsgrad tredje | Burn ShockForente stater
-
University of WashingtonFogarty International Center of the National Institute of HealthFullført
Kliniske studier på FE 202158 1.25
-
Changchun Intellicrown Pharmaceutical Co. LTDRekrutteringIkke-alkoholisk Steatohepatitt (NASH)Kina
-
GlyPharma TherapeuticsVectivBio AGTilbaketrukketLymfom, Non-Hodgkins, voksen | Lymfom, Hodgkins, voksen
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... og andre samarbeidspartnereFullførtJernmangel | Jernmangelanemi | Jernmangel (uten anemi)Peru
-
Ferring PharmaceuticalsFullførtProstatakreftStorbritannia
-
Ferring PharmaceuticalsFullførtHyperfagi i Prader-Willi syndromForente stater
-
Ferring PharmaceuticalsAvsluttet
-
Swiss Federal Institute of TechnologyUniversity of MalawiFullførtJernmangel | JernmangelanemiMalawi, Sveits
-
Ferring PharmaceuticalsFullførtLutealt hormontilskuddJapan
-
Swiss Federal Institute of TechnologyFullførtMalaria, Falciparum | Hakeorm infeksjoner | Schistosoma HaematobiumElfenbenskysten
-
IRCCS San RaffaeleFullført